Loading...

Targeting β-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations

BACKGROUND: Mitogen-activated protein kinases (MEK 1/2) are central components of the RAS signalling pathway and are attractive targets for cancer therapy. These agents continue to be investigated in KRAS mutant colon cancer but are met with significant resistance. Clinical investigations have demon...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Br J Cancer
Main Authors: Moon, Jai-Hee, Hong, Seung-Woo, Kim, Jeong Eun, Shin, Jae-Sik, Kim, Jin-Sun, Jung, Soo-A, Ha, Seung Hee, Lee, Seul, Kim, Joseph, Lee, Dae Hee, Park, Yoon Sun, Kim, Dong Min, Park, Sang-Soo, Hong, Jun Ki, Kim, Do Yeon, Kim, Eun Ho, Jung, Joonyee, Kim, Mi Jin, Kim, Seung-Mi, Deming, Dustin A., Kim, Kyunggon, Kim, Tae Won, Jin, Dong-Hoon
Format: Artigo
Sprog:Inglês
Udgivet: Nature Publishing Group UK 2019
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6734664/
https://ncbi.nlm.nih.gov/pubmed/30944457
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0434-5
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!